103 related articles for article (PubMed ID: 2783399)
1. Deficient interleukin-2-activated killer cell cytotoxicity in patients with systemic lupus erythematosus.
Froelich CJ; Guiffaut S; Sosenko M; Muth K
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):132-45. PubMed ID: 2783399
[TBL] [Abstract][Full Text] [Related]
2. Role of interleukin 2 in inducing normalization of natural killer activity in systemic lupus erythematosus.
Gaspar ML; Alvarez-Mon M; Gutiérrez C
Clin Immunol Immunopathol; 1988 Nov; 49(2):204-14. PubMed ID: 3139345
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus.
Tsokos GC; Smith PL; Christian CB; Lipnick RN; Balow JE; Djeu JY
Clin Immunol Immunopathol; 1985 Mar; 34(3):379-86. PubMed ID: 3156017
[TBL] [Abstract][Full Text] [Related]
4. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus.
Ewan PW; Barrett HM; Pusey CD
J Clin Lab Immunol; 1983 Feb; 10(2):71-6. PubMed ID: 6842577
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 activated cells from peripheral blood of patients with systemic lupus erythematosus.
Jira M; Strejcek J; Zavadil Z; Antosova E; Rejholec V
Z Rheumatol; 1990; 49(1):30-3. PubMed ID: 2327180
[TBL] [Abstract][Full Text] [Related]
6. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
7. Normal mitogen-induced suppression of the interleukin-6 (IL-6) response and its deficiency in systemic lupus erythematosus.
Warrington RJ; Rutherford WJ
J Clin Immunol; 1990 Jan; 10(1):52-60. PubMed ID: 2107195
[TBL] [Abstract][Full Text] [Related]
8. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor.
Balch CM; Itoh K; Tilden AB
Surgery; 1985 Aug; 98(2):151-7. PubMed ID: 3875156
[TBL] [Abstract][Full Text] [Related]
9. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
10. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
11. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event.
Katz P; Zaytoun AM; Lee JH; Panush RS; Longley S
J Immunol; 1982 Nov; 129(5):1966-71. PubMed ID: 7119439
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.
Sibbitt WL; Mathews PM; Bankhurst AD
J Clin Invest; 1983 May; 71(5):1230-9. PubMed ID: 6853711
[TBL] [Abstract][Full Text] [Related]
13. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
14. Abnormal interferon modulation of natural cytotoxicity in systemic lupus erythematosus. Relation to suppressive serum factors.
Sibbitt WL; Froelich CJ; Bankhurst AD
Arthritis Rheum; 1983 Dec; 26(12):1452-9. PubMed ID: 6651894
[TBL] [Abstract][Full Text] [Related]
15. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells.
Oshimi K; Oshimi Y; Saito H; Mizoguchi H
J Immunol Methods; 1988 May; 109(2):161-8. PubMed ID: 3258896
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
18. Expansion of lymphokine-activated killer cells for clinical use utilizing a novel culture device.
Colborn D; Rinehart J; Zwilling B; Irr J
J Immunol Methods; 1989 May; 119(2):247-54. PubMed ID: 2786037
[TBL] [Abstract][Full Text] [Related]
19. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon.
Ytterberg SR; Schnitzer TJ
Ann Rheum Dis; 1984 Jun; 43(3):457-61. PubMed ID: 6204601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
